Evidence map›Paper›PMID 36046180›Full record

ArticleClinical Medicine Insights. Cardiology2022

Influence of β

Eli F Kelley, Troy J Cross, Craig M McDonald, Cinrg Investigators, Eric P Hoffman, Christopher F Spurney, Luca Bello

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Eli F KelleyDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0001-8337-2253
Troy J CrossFaculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Craig M McDonaldUniversity of California Davis Medical Center, Sacramento, CA, USA.
Cinrg InvestigatorsDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Eric P HoffmanBinghamton University-SUNY, Binghamton, NY, USA.
Christopher F SpurneyDivision of Cardiology, Children's National Heart Institute, Children's National Hospital, Washington, DC, USA.
Luca BelloDepartment of Neurosciences, University of Padova, Padova, Italy.
Binghamton University · USChildren's National · USMayo Clinic in Arizona · USThe University of Sydney · AUUniversity of California Davis Medical Center · USUniversity of Padua · IT

Funding

Interdisciplinary Training in Lung Physiology and Biomedical EngineeringT32HL105355 · NHLBI · MAYO CLINIC ROCHESTER · PI PRAKASH, Y. S., SIECK, GARY C. · 2012 to 2021
$3.9M
NHLBI NIH HHS T32 HL105355
6 · The paper itself

Abstract

The purpose of this study was to determine whether the longitudinal progression of decline in left ventricular ejection fraction (LVEF) in Duchenne muscular dystrophy (DMD) patients is moderated by ADRB1 genotype and whether the efficacy of ß-blocker therapy is influenced by genotype status. About 147 DMD patients (6-34 years.) were analyzed with a focus on β

Indexed as

beta1-adrenergic receptorbeta-blockerscardiovascularDuchenne muscular dystrophygenotypeleft ventricular ejection fraction

Identifiers

PMID36046180
PMCPMC9421016
OpenAlexW4292876263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.